Fulgent Genetics (FLGT) Current Deferred Revenue (2018 - 2026)

Fulgent Genetics has reported Current Deferred Revenue for 9 years, with the latest figure at $3.4 million in Q2 2026.

• Quarterly Current Deferred Revenue rose 27.35% year-over-year to $3.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.4 million (up 27.35% YoY) and the FY2025 annual result came in at $3.6 million, up 62.71% from the prior year.
• Current Deferred Revenue grew to $3.4 million in Q2 2026 per FLGT's latest filing, from $3.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $14.1 million in Q1 2022 and troughed at $2.2 million in Q4 2024.
• A 5-year average of $3.9 million and a median of $2.8 million in 2024 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue plunged 80.62% in 2023, then jumped 62.71% in 2025.
• Over 5 years, Current Deferred Revenue stood at $3.2 million in 2022, then fell by 10.16% to $2.9 million in 2023, then decreased by 22.27% to $2.2 million in 2024, then surged by 62.71% to $3.6 million in 2025, then retreated by 6.35% to $3.4 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $3.4 million, $3.0 million, and $3.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.